<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02547649</url>
  </required_header>
  <id_info>
    <org_study_id>V114-006</org_study_id>
    <secondary_id>V114-006</secondary_id>
    <nct_id>NCT02547649</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)</brief_title>
  <official_title>A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, and immunogenicity of a
      single dose of different formulations of V114 (V114-A and V114-B) and Prevnar 13®
      (pneumococcal 13-valent conjugate vaccine) in adult participants

      ≥50 years of age in good health.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 8, 2015</start_date>
  <completion_date type="Actual">January 20, 2016</completion_date>
  <primary_completion_date type="Actual">January 20, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With an Adverse Event (AE)</measure>
    <time_frame>Up to 14 days after vaccination</time_frame>
    <description>The percentage of participants experiencing ≥1 AE(s) in each arm was determined. An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With a Solicited Injection-site Adverse Event (AE)</measure>
    <time_frame>Up to 14 days after vaccination</time_frame>
    <description>The percentage of participants experiencing ≥1 solicited injection-site AE(s) in each arm was determined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With a Solicited Systemic Adverse Event (AE)</measure>
    <time_frame>Up to 14 days after vaccination</time_frame>
    <description>The percentage of participants experiencing ≥1 solicited systemic AE(s) in each arm was determined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With a Serious Adverse Event (SAE)</measure>
    <time_frame>Up to 30 days after vaccination</time_frame>
    <description>The percentage of participants experiencing ≥1 SAE(s) in each arm was determined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Vaccine-Related Serious Adverse Event (SAE)</measure>
    <time_frame>Up to 30 days after vaccination</time_frame>
    <description>The percentage of participants experiencing ≥1 vaccine-related SAEs(s) in each arm was determined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) of Serotype-specific Opsonophagocytic Killing Activity (OPA) at One Month Post-Vaccination</measure>
    <time_frame>Day 30 (one month after vaccination)</time_frame>
    <description>The OPA GMTs of each common serotype (CS) and V114-specific serotype (VS) were determined in each arm. Titer levels were determined with the multiplexed opsonophagocytic assay (MOPA).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentrations (GMCs) of Serotype-specific Immunoglobulin G (IgG) at One Month Post-Vaccination</measure>
    <time_frame>Day 30 (one month after vaccination)</time_frame>
    <description>The IgG GMCs of each common pneumococcal serotype (CS) and V114-specific pneumococcal serotype (VS) were determined for each arm. Concentrations were determined with pneumococcal electrochemiluminescence (PnECL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a ≥4-fold Rise From Baseline in Serotype-specific Opsonophagocytic Killing Activity (OPA) Geometric Mean Titers (GMTs)</measure>
    <time_frame>Baseline and Day 30 (one month after vaccination)</time_frame>
    <description>The percentage of participants with ≥4-fold rise from baseline in OPA GMTs of each common serotype (CS) and V114-specific serotype (VS) were compared in the V114 and Prevnar® 13 arms. Estimated GMT, GMT ratio, 95% CI, and p-values were obtained from a constrained longitudinal data analysis (cLDA) model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a ≥4-fold Rise From Baseline in Geometric Mean Concentrations (GMCs) of Serotype-specific Immunoglobulin G (IgG) Antibodies</measure>
    <time_frame>Baseline and Day 30 (one month after vaccination)</time_frame>
    <description>The percentage of participants with ≥4-fold rise from baseline in IgG GMCs of each common serotype (CS) and V114-specific serotype (VS) were compared in the V114 and Prevnar® 13 arms. Estimated GMT, GMT ratio, 95% CI, and p-values were obtained from a constrained longitudinal data analysis (cLDA) model.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">690</enrollment>
  <condition>Pneumococcal Infections</condition>
  <arm_group>
    <arm_group_label>V114 Formulation A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a single 0.5 mL intramuscular injection of V114 Formulation A on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V114 Formulation B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a single 0.5 mL intramuscular injection of V114 Formulation B on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prevnar 13®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive a single 0.5 mL intramuscular injection of Prevnar 13® on Day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V114-A</intervention_name>
    <description>Formulation A of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-A uses a unique excipient to improve stability of the vaccine against physical stress).</description>
    <arm_group_label>V114 Formulation A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V114-B</intervention_name>
    <description>Formulation B of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-B uses a unique excipient to improve stability of the vaccine against physical stress).</description>
    <arm_group_label>V114 Formulation B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevnar 13®</intervention_name>
    <description>Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each), and 6B (4.4 mcg) in each 0.5 mL dose.</description>
    <arm_group_label>Prevnar 13®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Good health; any underlying chronic illness must be documented to be in stable
             condition

          -  Highly unlikely to conceive through 6 weeks after administration of the study vaccine

        Exclusion Criteria:

          -  Prior administration of any pneumococcal vaccine

          -  History of invasive pneumococcal disease (IPD) [positive blood culture, positive
             cerebrospinal fluid culture, or other sterile site) or known history of other
             culture-positive pneumococcal disease

          -  Known hypersensitivity to any vaccine component

          -  Known or suspected impairment of immune function

          -  Received systemic corticosteroids for &gt;=14 consecutive days and has not completed
             treatment &lt;=30 days prior to study entry, or received systemic corticosteroids
             exceeding physiologic replacement doses within 14 days prior to study vaccination

          -  Coagulation disorder contraindicating intramuscular vaccination

          -  Receives immunosuppressive therapy, including chemotherapeutic agents used to treat
             cancer or other conditions, and treatments associated with organ or bone marrow
             transplantation, or autoimmune disease

          -  Received a blood transfusion or blood products, including immunoglobulins within the 6
             months before receipt of study vaccine or is scheduled to receive a blood transfusion
             or blood product within 30 days of receipt of study vaccine. Autologous blood
             transfusions are not considered an exclusion criterion.

          -  Participated in another clinical study of an investigational product within 2 months
             before the beginning of or any time during the duration of the current clinical study

          -  Breast feeding

          -  User of recreational or illicit drugs or has had a recent history (within the last
             year) of drug or alcohol abuse or dependence
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>September 10, 2015</study_first_submitted>
  <study_first_submitted_qc>September 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2015</study_first_posted>
  <results_first_submitted>March 8, 2019</results_first_submitted>
  <results_first_submitted_qc>March 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 2, 2019</results_first_posted>
  <last_update_submitted>April 9, 2019</last_update_submitted>
  <last_update_submitted_qc>April 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Healthy, pneumococcal vaccine-naïve adults ≥50 years of age were recruited at 23 sites in the United States.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>V114-A</title>
          <description>Participants receive a single 0.5 mL intramuscular injection of V114 Formulation A on Day 1. Formulation A of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-A uses a unique excipient to improve stability of the vaccine against physical stress).</description>
        </group>
        <group group_id="P2">
          <title>V114-B</title>
          <description>Participants receive a single 0.5 mL intramuscular injection of V114 Formulation B on Day 1. Formulation B of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-B uses a unique excipient to improve stability of the vaccine against physical stress).</description>
        </group>
        <group group_id="P3">
          <title>Prevnar 13®</title>
          <description>Participants receive a single 0.5 mL intramuscular injection of Prevnar 13™ on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="231"/>
                <participants group_id="P2" count="231"/>
                <participants group_id="P3" count="228"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated</title>
              <participants_list>
                <participants group_id="P1" count="231"/>
                <participants group_id="P2" count="231"/>
                <participants group_id="P3" count="227"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="228"/>
                <participants group_id="P2" count="226"/>
                <participants group_id="P3" count="224"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not vaccinated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Baseline Analysis Population consists of all vaccinated participants.</population>
      <group_list>
        <group group_id="B1">
          <title>V114-A</title>
          <description>Participants receive a single 0.5 mL intramuscular injection of V114 Formulation A on Day 1. Formulation A of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-A uses a unique excipient to improve stability of the vaccine against physical stress).</description>
        </group>
        <group group_id="B2">
          <title>V114-B</title>
          <description>Participants receive a single 0.5 mL intramuscular injection of V114 Formulation B on Day 1. Formulation B of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-B uses a unique excipient to improve stability of the vaccine against physical stress).</description>
        </group>
        <group group_id="B3">
          <title>Prevnar 13®</title>
          <description>Participants receive a single 0.5 mL intramuscular injection of Prevnar 13™ on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="231"/>
            <count group_id="B2" value="231"/>
            <count group_id="B3" value="227"/>
            <count group_id="B4" value="689"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.4" spread="8.3"/>
                    <measurement group_id="B2" value="63.4" spread="8.3"/>
                    <measurement group_id="B3" value="63.1" spread="8.1"/>
                    <measurement group_id="B4" value="63.3" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="133"/>
                    <measurement group_id="B4" value="385"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="94"/>
                    <measurement group_id="B4" value="304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With an Adverse Event (AE)</title>
        <description>The percentage of participants experiencing ≥1 AE(s) in each arm was determined. An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
        <time_frame>Up to 14 days after vaccination</time_frame>
        <population>All participants who received study vaccination are included.</population>
        <group_list>
          <group group_id="O1">
            <title>V114-A</title>
            <description>Participants receive a single 0.5 mL intramuscular injection of V114 Formulation A on Day 1. Formulation A of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-A uses a unique excipient to improve stability of the vaccine against physical stress).</description>
          </group>
          <group group_id="O2">
            <title>V114-B</title>
            <description>Participants receive a single 0.5 mL intramuscular injection of V114 Formulation B on Day 1. Formulation B of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-B uses a unique excipient to improve stability of the vaccine against physical stress).</description>
          </group>
          <group group_id="O3">
            <title>Prevnar 13®</title>
            <description>Participants receive a single 0.5 mL intramuscular injection of Prevnar 13™ on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Adverse Event (AE)</title>
          <description>The percentage of participants experiencing ≥1 AE(s) in each arm was determined. An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
          <population>All participants who received study vaccination are included.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
                <count group_id="O2" value="231"/>
                <count group_id="O3" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.9"/>
                    <measurement group_id="O2" value="72.3"/>
                    <measurement group_id="O3" value="67.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Solicited Injection-site Adverse Event (AE)</title>
        <description>The percentage of participants experiencing ≥1 solicited injection-site AE(s) in each arm was determined.</description>
        <time_frame>Up to 14 days after vaccination</time_frame>
        <population>All participants who received study vaccination are included.</population>
        <group_list>
          <group group_id="O1">
            <title>V114-A</title>
            <description>Participants receive a single 0.5 mL intramuscular injection of V114 Formulation A on Day 1. Formulation A of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-A uses a unique excipient to improve stability of the vaccine against physical stress).</description>
          </group>
          <group group_id="O2">
            <title>V114-B</title>
            <description>Participants receive a single 0.5 mL intramuscular injection of V114 Formulation B on Day 1. Formulation B of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-B uses a unique excipient to improve stability of the vaccine against physical stress).</description>
          </group>
          <group group_id="O3">
            <title>Prevnar 13®</title>
            <description>Participants receive a single 0.5 mL intramuscular injection of Prevnar 13™ on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Solicited Injection-site Adverse Event (AE)</title>
          <description>The percentage of participants experiencing ≥1 solicited injection-site AE(s) in each arm was determined.</description>
          <population>All participants who received study vaccination are included.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
                <count group_id="O2" value="231"/>
                <count group_id="O3" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7"/>
                    <measurement group_id="O2" value="11.3"/>
                    <measurement group_id="O3" value="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.3"/>
                    <measurement group_id="O2" value="60.2"/>
                    <measurement group_id="O3" value="52.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7"/>
                    <measurement group_id="O2" value="16.5"/>
                    <measurement group_id="O3" value="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Solicited Systemic Adverse Event (AE)</title>
        <description>The percentage of participants experiencing ≥1 solicited systemic AE(s) in each arm was determined.</description>
        <time_frame>Up to 14 days after vaccination</time_frame>
        <population>All participants who received study vaccination are included.</population>
        <group_list>
          <group group_id="O1">
            <title>V114-A</title>
            <description>Participants receive a single 0.5 mL intramuscular injection of V114 Formulation A on Day 1. Formulation A of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-A uses a unique excipient to improve stability of the vaccine against physical stress).</description>
          </group>
          <group group_id="O2">
            <title>V114-B</title>
            <description>Participants receive a single 0.5 mL intramuscular injection of V114 Formulation B on Day 1. Formulation B of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-B uses a unique excipient to improve stability of the vaccine against physical stress).</description>
          </group>
          <group group_id="O3">
            <title>Prevnar 13®</title>
            <description>Participants receive a single 0.5 mL intramuscular injection of Prevnar 13™ on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Solicited Systemic Adverse Event (AE)</title>
          <description>The percentage of participants experiencing ≥1 solicited systemic AE(s) in each arm was determined.</description>
          <population>All participants who received study vaccination are included.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
                <count group_id="O2" value="231"/>
                <count group_id="O3" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                    <measurement group_id="O2" value="7.4"/>
                    <measurement group_id="O3" value="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.9"/>
                    <measurement group_id="O2" value="18.6"/>
                    <measurement group_id="O3" value="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1"/>
                    <measurement group_id="O2" value="12.6"/>
                    <measurement group_id="O3" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.2"/>
                    <measurement group_id="O2" value="17.7"/>
                    <measurement group_id="O3" value="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Serious Adverse Event (SAE)</title>
        <description>The percentage of participants experiencing ≥1 SAE(s) in each arm was determined.</description>
        <time_frame>Up to 30 days after vaccination</time_frame>
        <population>All participants who received study vaccination are included.</population>
        <group_list>
          <group group_id="O1">
            <title>V114-A</title>
            <description>Participants receive a single 0.5 mL intramuscular injection of V114 Formulation A on Day 1. Formulation A of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-A uses a unique excipient to improve stability of the vaccine against physical stress).</description>
          </group>
          <group group_id="O2">
            <title>V114-B</title>
            <description>Participants receive a single 0.5 mL intramuscular injection of V114 Formulation B on Day 1. Formulation B of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-B uses a unique excipient to improve stability of the vaccine against physical stress).</description>
          </group>
          <group group_id="O3">
            <title>Prevnar 13®</title>
            <description>Participants receive a single 0.5 mL intramuscular injection of Prevnar 13™ on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Serious Adverse Event (SAE)</title>
          <description>The percentage of participants experiencing ≥1 SAE(s) in each arm was determined.</description>
          <population>All participants who received study vaccination are included.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
                <count group_id="O2" value="231"/>
                <count group_id="O3" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0.9"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Vaccine-Related Serious Adverse Event (SAE)</title>
        <description>The percentage of participants experiencing ≥1 vaccine-related SAEs(s) in each arm was determined.</description>
        <time_frame>Up to 30 days after vaccination</time_frame>
        <population>All participants who received study vaccination are included.</population>
        <group_list>
          <group group_id="O1">
            <title>V114-A</title>
            <description>Participants receive a single 0.5 mL intramuscular injection of V114 Formulation A on Day 1. Formulation A of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-A uses a unique excipient to improve stability of the vaccine against physical stress).</description>
          </group>
          <group group_id="O2">
            <title>V114-B</title>
            <description>Participants receive a single 0.5 mL intramuscular injection of V114 Formulation B on Day 1. Formulation B of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-B uses a unique excipient to improve stability of the vaccine against physical stress).</description>
          </group>
          <group group_id="O3">
            <title>Prevnar 13®</title>
            <description>Participants receive a single 0.5 mL intramuscular injection of Prevnar 13™ on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Vaccine-Related Serious Adverse Event (SAE)</title>
          <description>The percentage of participants experiencing ≥1 vaccine-related SAEs(s) in each arm was determined.</description>
          <population>All participants who received study vaccination are included.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
                <count group_id="O2" value="231"/>
                <count group_id="O3" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) of Serotype-specific Opsonophagocytic Killing Activity (OPA) at One Month Post-Vaccination</title>
        <description>The OPA GMTs of each common serotype (CS) and V114-specific serotype (VS) were determined in each arm. Titer levels were determined with the multiplexed opsonophagocytic assay (MOPA).</description>
        <time_frame>Day 30 (one month after vaccination)</time_frame>
        <population>All vaccinated participants with data available are included.</population>
        <group_list>
          <group group_id="O1">
            <title>V114-A</title>
            <description>Participants receive a single 0.5 mL intramuscular injection of V114 Formulation A on Day 1. Formulation A of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-A uses a unique excipient to improve stability of the vaccine against physical stress).</description>
          </group>
          <group group_id="O2">
            <title>V114-B</title>
            <description>Participants receive a single 0.5 mL intramuscular injection of V114 Formulation B on Day 1. Formulation B of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-B uses a unique excipient to improve stability of the vaccine against physical stress).</description>
          </group>
          <group group_id="O3">
            <title>Prevnar 13®</title>
            <description>Participants receive a single 0.5 mL intramuscular injection of Prevnar 13™ on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) of Serotype-specific Opsonophagocytic Killing Activity (OPA) at One Month Post-Vaccination</title>
          <description>The OPA GMTs of each common serotype (CS) and V114-specific serotype (VS) were determined in each arm. Titer levels were determined with the multiplexed opsonophagocytic assay (MOPA).</description>
          <population>All vaccinated participants with data available are included.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
                <count group_id="O2" value="231"/>
                <count group_id="O3" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CS1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="209"/>
                    <count group_id="O2" value="203"/>
                    <count group_id="O3" value="204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196.79" lower_limit="145.49" upper_limit="266.17"/>
                    <measurement group_id="O2" value="144.01" lower_limit="106.06" upper_limit="195.54"/>
                    <measurement group_id="O3" value="127.19" lower_limit="93.19" upper_limit="173.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="206"/>
                    <count group_id="O2" value="203"/>
                    <count group_id="O3" value="199"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.78" lower_limit="83.69" upper_limit="131.18"/>
                    <measurement group_id="O2" value="61.41" lower_limit="48.99" upper_limit="76.97"/>
                    <measurement group_id="O3" value="33.10" lower_limit="25.41" upper_limit="43.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="213"/>
                    <count group_id="O2" value="206"/>
                    <count group_id="O3" value="210"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1314.31" lower_limit="1050.53" upper_limit="1644.31"/>
                    <measurement group_id="O2" value="929.53" lower_limit="722.68" upper_limit="1195.57"/>
                    <measurement group_id="O3" value="1195.73" lower_limit="931.75" upper_limit="1534.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="212"/>
                    <count group_id="O2" value="204"/>
                    <count group_id="O3" value="206"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="273.79" lower_limit="201.52" upper_limit="372.00"/>
                    <measurement group_id="O2" value="269.14" lower_limit="197.57" upper_limit="366.63"/>
                    <measurement group_id="O3" value="283.83" lower_limit="209.93" upper_limit="383.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS6A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="214"/>
                    <count group_id="O2" value="213"/>
                    <count group_id="O3" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3849.02" lower_limit="2937.54" upper_limit="5043.31"/>
                    <measurement group_id="O2" value="4690.40" lower_limit="3688.20" upper_limit="5964.93"/>
                    <measurement group_id="O3" value="4932.72" lower_limit="3771.98" upper_limit="6450.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS6B</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="212"/>
                    <count group_id="O2" value="212"/>
                    <count group_id="O3" value="208"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4552.54" lower_limit="3680.12" upper_limit="5631.79"/>
                    <measurement group_id="O2" value="5082.56" lower_limit="3984.20" upper_limit="6483.72"/>
                    <measurement group_id="O3" value="3909.05" lower_limit="3005.43" upper_limit="5084.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS7F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="212"/>
                    <count group_id="O2" value="210"/>
                    <count group_id="O3" value="210"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2672.91" lower_limit="2213.60" upper_limit="3227.51"/>
                    <measurement group_id="O2" value="2845.64" lower_limit="2374.74" upper_limit="3409.92"/>
                    <measurement group_id="O3" value="3659.86" lower_limit="3036.53" upper_limit="4411.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS9V</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="215"/>
                    <count group_id="O2" value="211"/>
                    <count group_id="O3" value="208"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2514.21" lower_limit="2014.06" upper_limit="3138.57"/>
                    <measurement group_id="O2" value="1962.09" lower_limit="1558.28" upper_limit="2470.55"/>
                    <measurement group_id="O3" value="2112.91" lower_limit="1685.97" upper_limit="2647.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="214"/>
                    <count group_id="O2" value="210"/>
                    <count group_id="O3" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3496.71" lower_limit="2776.80" upper_limit="4403.25"/>
                    <measurement group_id="O2" value="2664.63" lower_limit="2206.92" upper_limit="3217.26"/>
                    <measurement group_id="O3" value="3111.50" lower_limit="2560.29" upper_limit="3781.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS18C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="214"/>
                    <count group_id="O2" value="213"/>
                    <count group_id="O3" value="209"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1896.14" lower_limit="1540.37" upper_limit="2334.08"/>
                    <measurement group_id="O2" value="2687.10" lower_limit="2169.85" upper_limit="3327.65"/>
                    <measurement group_id="O3" value="1528.79" lower_limit="1208.83" upper_limit="1933.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS19A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="211"/>
                    <count group_id="O2" value="213"/>
                    <count group_id="O3" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1910.75" lower_limit="1587.43" upper_limit="2299.92"/>
                    <measurement group_id="O2" value="2477.75" lower_limit="2043.94" upper_limit="3003.63"/>
                    <measurement group_id="O3" value="2045.57" lower_limit="1692.29" upper_limit="2472.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS19F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="213"/>
                    <count group_id="O3" value="209"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="799.86" lower_limit="636.72" upper_limit="1004.80"/>
                    <measurement group_id="O2" value="1084.99" lower_limit="855.50" upper_limit="1376.04"/>
                    <measurement group_id="O3" value="810.05" lower_limit="640.41" upper_limit="1024.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS23F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="213"/>
                    <count group_id="O2" value="206"/>
                    <count group_id="O3" value="211"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1233.60" lower_limit="943.88" upper_limit="1612.25"/>
                    <measurement group_id="O2" value="2198.15" lower_limit="1702.57" upper_limit="2837.99"/>
                    <measurement group_id="O3" value="1561.04" lower_limit="1171.58" upper_limit="2079.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VS22F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="206"/>
                    <count group_id="O2" value="204"/>
                    <count group_id="O3" value="189"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4743.78" lower_limit="3737.99" upper_limit="6020.21"/>
                    <measurement group_id="O2" value="3976.66" lower_limit="3141.02" upper_limit="5034.61"/>
                    <measurement group_id="O3" value="68.47" lower_limit="48.39" upper_limit="96.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VS33F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="212"/>
                    <count group_id="O2" value="207"/>
                    <count group_id="O3" value="194"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12457.52" lower_limit="10076.61" upper_limit="15401.00"/>
                    <measurement group_id="O2" value="12614.22" lower_limit="10236.84" upper_limit="15543.72"/>
                    <measurement group_id="O3" value="2111.66" lower_limit="1681.43" upper_limit="2651.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentrations (GMCs) of Serotype-specific Immunoglobulin G (IgG) at One Month Post-Vaccination</title>
        <description>The IgG GMCs of each common pneumococcal serotype (CS) and V114-specific pneumococcal serotype (VS) were determined for each arm. Concentrations were determined with pneumococcal electrochemiluminescence (PnECL).</description>
        <time_frame>Day 30 (one month after vaccination)</time_frame>
        <population>All vaccinated participants with data available are included.</population>
        <group_list>
          <group group_id="O1">
            <title>V114-A</title>
            <description>Participants receive a single 0.5 mL intramuscular injection of V114 Formulation A on Day 1. Formulation A of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-A uses a unique excipient to improve stability of the vaccine against physical stress).</description>
          </group>
          <group group_id="O2">
            <title>V114-B</title>
            <description>Participants receive a single 0.5 mL intramuscular injection of V114 Formulation B on Day 1. Formulation B of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-B uses a unique excipient to improve stability of the vaccine against physical stress).</description>
          </group>
          <group group_id="O3">
            <title>Prevnar 13®</title>
            <description>Participants receive a single 0.5 mL intramuscular injection of Prevnar 13™ on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations (GMCs) of Serotype-specific Immunoglobulin G (IgG) at One Month Post-Vaccination</title>
          <description>The IgG GMCs of each common pneumococcal serotype (CS) and V114-specific pneumococcal serotype (VS) were determined for each arm. Concentrations were determined with pneumococcal electrochemiluminescence (PnECL).</description>
          <population>All vaccinated participants with data available are included.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
                <count group_id="O2" value="231"/>
                <count group_id="O3" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CS1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="215"/>
                    <count group_id="O3" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.04" lower_limit="4.10" upper_limit="6.19"/>
                    <measurement group_id="O2" value="4.00" lower_limit="3.34" upper_limit="4.79"/>
                    <measurement group_id="O3" value="4.15" lower_limit="3.40" upper_limit="5.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="215"/>
                    <count group_id="O3" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" lower_limit="0.78" upper_limit="1.12"/>
                    <measurement group_id="O2" value="0.61" lower_limit="0.51" upper_limit="0.72"/>
                    <measurement group_id="O3" value="0.48" lower_limit="0.39" upper_limit="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="215"/>
                    <count group_id="O3" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.30" lower_limit="1.07" upper_limit="1.58"/>
                    <measurement group_id="O2" value="0.96" lower_limit="0.79" upper_limit="1.16"/>
                    <measurement group_id="O3" value="1.39" lower_limit="1.12" upper_limit="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="215"/>
                    <count group_id="O3" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.93" lower_limit="3.08" upper_limit="5.02"/>
                    <measurement group_id="O2" value="3.40" lower_limit="2.66" upper_limit="4.34"/>
                    <measurement group_id="O3" value="3.37" lower_limit="2.66" upper_limit="4.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS6A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="215"/>
                    <count group_id="O3" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.88" lower_limit="2.98" upper_limit="5.06"/>
                    <measurement group_id="O2" value="4.56" lower_limit="3.49" upper_limit="5.96"/>
                    <measurement group_id="O3" value="4.40" lower_limit="3.29" upper_limit="5.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS6B</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="215"/>
                    <count group_id="O3" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.58" lower_limit="2.78" upper_limit="4.63"/>
                    <measurement group_id="O2" value="4.71" lower_limit="3.58" upper_limit="6.20"/>
                    <measurement group_id="O3" value="3.63" lower_limit="2.72" upper_limit="4.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS7F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="215"/>
                    <count group_id="O3" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.19" lower_limit="3.41" upper_limit="5.15"/>
                    <measurement group_id="O2" value="4.43" lower_limit="3.59" upper_limit="5.47"/>
                    <measurement group_id="O3" value="4.69" lower_limit="3.78" upper_limit="5.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS9V</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="215"/>
                    <count group_id="O3" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.17" lower_limit="3.39" upper_limit="5.12"/>
                    <measurement group_id="O2" value="3.73" lower_limit="3.04" upper_limit="4.56"/>
                    <measurement group_id="O3" value="3.40" lower_limit="2.74" upper_limit="4.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="215"/>
                    <count group_id="O3" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.54" lower_limit="8.36" upper_limit="13.30"/>
                    <measurement group_id="O2" value="6.51" lower_limit="5.23" upper_limit="8.11"/>
                    <measurement group_id="O3" value="7.31" lower_limit="5.79" upper_limit="9.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS18C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="215"/>
                    <count group_id="O3" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.45" lower_limit="5.21" upper_limit="7.98"/>
                    <measurement group_id="O2" value="6.51" lower_limit="5.23" upper_limit="8.11"/>
                    <measurement group_id="O3" value="7.31" lower_limit="5.79" upper_limit="9.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS19A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="215"/>
                    <count group_id="O3" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.12" lower_limit="6.63" upper_limit="9.94"/>
                    <measurement group_id="O2" value="14.89" lower_limit="12.20" upper_limit="18.18"/>
                    <measurement group_id="O3" value="10.42" lower_limit="8.66" upper_limit="12.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS19F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="215"/>
                    <count group_id="O3" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.96" lower_limit="3.14" upper_limit="4.98"/>
                    <measurement group_id="O2" value="7.17" lower_limit="5.67" upper_limit="9.05"/>
                    <measurement group_id="O3" value="4.65" lower_limit="3.81" upper_limit="5.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS23F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="215"/>
                    <count group_id="O3" value="216"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.88" lower_limit="3.03" upper_limit="4.97"/>
                    <measurement group_id="O2" value="5.49" lower_limit="4.25" upper_limit="7.09"/>
                    <measurement group_id="O3" value="4.27" lower_limit="3.27" upper_limit="5.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VS22F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="215"/>
                    <count group_id="O3" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.05" lower_limit="2.48" upper_limit="3.75"/>
                    <measurement group_id="O2" value="2.75" lower_limit="2.25" upper_limit="3.36"/>
                    <measurement group_id="O3" value="0.25" lower_limit="0.20" upper_limit="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VS33F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="215"/>
                    <count group_id="O3" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.28" lower_limit="8.33" upper_limit="12.67"/>
                    <measurement group_id="O2" value="7.46" lower_limit="6.01" upper_limit="9.26"/>
                    <measurement group_id="O3" value="0.76" lower_limit="0.60" upper_limit="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a ≥4-fold Rise From Baseline in Serotype-specific Opsonophagocytic Killing Activity (OPA) Geometric Mean Titers (GMTs)</title>
        <description>The percentage of participants with ≥4-fold rise from baseline in OPA GMTs of each common serotype (CS) and V114-specific serotype (VS) were compared in the V114 and Prevnar® 13 arms. Estimated GMT, GMT ratio, 95% CI, and p-values were obtained from a constrained longitudinal data analysis (cLDA) model.</description>
        <time_frame>Baseline and Day 30 (one month after vaccination)</time_frame>
        <population>All vaccinated participants with data available are included.</population>
        <group_list>
          <group group_id="O1">
            <title>V114-A</title>
            <description>Participants receive a single 0.5 mL intramuscular injection of V114 Formulation A on Day 1. Formulation A of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-A uses a unique excipient to improve stability of the vaccine against physical stress).</description>
          </group>
          <group group_id="O2">
            <title>V114-B</title>
            <description>Participants receive a single 0.5 mL intramuscular injection of V114 Formulation B on Day 1. Formulation B of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-B uses a unique excipient to improve stability of the vaccine against physical stress).</description>
          </group>
          <group group_id="O3">
            <title>Prevnar 13®</title>
            <description>Participants receive a single 0.5 mL intramuscular injection of Prevnar 13™ on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a ≥4-fold Rise From Baseline in Serotype-specific Opsonophagocytic Killing Activity (OPA) Geometric Mean Titers (GMTs)</title>
          <description>The percentage of participants with ≥4-fold rise from baseline in OPA GMTs of each common serotype (CS) and V114-specific serotype (VS) were compared in the V114 and Prevnar® 13 arms. Estimated GMT, GMT ratio, 95% CI, and p-values were obtained from a constrained longitudinal data analysis (cLDA) model.</description>
          <population>All vaccinated participants with data available are included.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
                <count group_id="O2" value="231"/>
                <count group_id="O3" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CS1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="203"/>
                    <count group_id="O2" value="199"/>
                    <count group_id="O3" value="201"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.9" lower_limit="64.17" upper_limit="77.08"/>
                    <measurement group_id="O2" value="66.3" lower_limit="59.31" upper_limit="72.86"/>
                    <measurement group_id="O3" value="61.7" lower_limit="54.59" upper_limit="68.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="202"/>
                    <count group_id="O2" value="201"/>
                    <count group_id="O3" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.8" lower_limit="65.04" upper_limit="77.87"/>
                    <measurement group_id="O2" value="64.2" lower_limit="57.13" upper_limit="70.80"/>
                    <measurement group_id="O3" value="44.1" lower_limit="37.01" upper_limit="51.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="180"/>
                    <count group_id="O3" value="185"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.8" lower_limit="78.93" upper_limit="89.59"/>
                    <measurement group_id="O2" value="78.9" lower_limit="72.19" upper_limit="84.61"/>
                    <measurement group_id="O3" value="81.6" lower_limit="75.28" upper_limit="86.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="195"/>
                    <count group_id="O2" value="194"/>
                    <count group_id="O3" value="198"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.2" lower_limit="61.17" upper_limit="74.67"/>
                    <measurement group_id="O2" value="70.6" lower_limit="63.67" upper_limit="76.93"/>
                    <measurement group_id="O3" value="67.2" lower_limit="60.16" upper_limit="73.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS6A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="201"/>
                    <count group_id="O2" value="199"/>
                    <count group_id="O3" value="199"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.1" lower_limit="79.38" upper_limit="89.70"/>
                    <measurement group_id="O2" value="82.9" lower_limit="76.95" upper_limit="87.87"/>
                    <measurement group_id="O3" value="82.9" lower_limit="76.95" upper_limit="87.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS6B</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="185"/>
                    <count group_id="O2" value="181"/>
                    <count group_id="O3" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.0" lower_limit="81.31" upper_limit="91.51"/>
                    <measurement group_id="O2" value="87.3" lower_limit="81.55" upper_limit="91.77"/>
                    <measurement group_id="O3" value="84.2" lower_limit="78.04" upper_limit="89.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS7F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                    <count group_id="O2" value="191"/>
                    <count group_id="O3" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.9" lower_limit="60.71" upper_limit="74.54"/>
                    <measurement group_id="O2" value="74.3" lower_limit="67.54" upper_limit="80.38"/>
                    <measurement group_id="O3" value="75.0" lower_limit="68.18" upper_limit="81.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS9V</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="195"/>
                    <count group_id="O2" value="188"/>
                    <count group_id="O3" value="190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.6" lower_limit="57.46" upper_limit="71.31"/>
                    <measurement group_id="O2" value="59.6" lower_limit="52.19" upper_limit="66.65"/>
                    <measurement group_id="O3" value="60.5" lower_limit="53.19" upper_limit="67.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="198"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="205"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.6" lower_limit="54.46" upper_limit="68.42"/>
                    <measurement group_id="O2" value="50.3" lower_limit="43.06" upper_limit="57.44"/>
                    <measurement group_id="O3" value="48.3" lower_limit="41.28" upper_limit="55.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS18C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="185"/>
                    <count group_id="O3" value="185"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.9" lower_limit="68.10" upper_limit="80.85"/>
                    <measurement group_id="O2" value="73.0" lower_limit="65.97" upper_limit="79.23"/>
                    <measurement group_id="O3" value="64.3" lower_limit="56.96" upper_limit="71.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS19A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                    <count group_id="O2" value="196"/>
                    <count group_id="O3" value="197"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.9" lower_limit="68.02" upper_limit="80.91"/>
                    <measurement group_id="O2" value="73.0" lower_limit="66.17" upper_limit="79.04"/>
                    <measurement group_id="O3" value="71.1" lower_limit="64.19" upper_limit="77.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS19F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="198"/>
                    <count group_id="O2" value="201"/>
                    <count group_id="O3" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.2" lower_limit="67.59" upper_limit="80.18"/>
                    <measurement group_id="O2" value="72.1" lower_limit="65.40" upper_limit="78.22"/>
                    <measurement group_id="O3" value="75.5" lower_limit="68.94" upper_limit="81.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS22F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="158"/>
                    <count group_id="O2" value="166"/>
                    <count group_id="O3" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.6" lower_limit="69.20" upper_limit="82.94"/>
                    <measurement group_id="O2" value="71.1" lower_limit="63.55" upper_limit="77.85"/>
                    <measurement group_id="O3" value="14.5" lower_limit="9.55" upper_limit="20.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VS23F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="194"/>
                    <count group_id="O2" value="185"/>
                    <count group_id="O3" value="190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.3" lower_limit="69.67" upper_limit="82.09"/>
                    <measurement group_id="O2" value="81.1" lower_limit="74.68" upper_limit="86.45"/>
                    <measurement group_id="O3" value="78.9" lower_limit="72.46" upper_limit="84.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VS33F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                    <count group_id="O2" value="182"/>
                    <count group_id="O3" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.5" lower_limit="46.05" upper_limit="60.79"/>
                    <measurement group_id="O2" value="58.8" lower_limit="51.27" upper_limit="66.02"/>
                    <measurement group_id="O3" value="8.8" lower_limit="4.99" upper_limit="14.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a ≥4-fold Rise From Baseline in Geometric Mean Concentrations (GMCs) of Serotype-specific Immunoglobulin G (IgG) Antibodies</title>
        <description>The percentage of participants with ≥4-fold rise from baseline in IgG GMCs of each common serotype (CS) and V114-specific serotype (VS) were compared in the V114 and Prevnar® 13 arms. Estimated GMT, GMT ratio, 95% CI, and p-values were obtained from a constrained longitudinal data analysis (cLDA) model.</description>
        <time_frame>Baseline and Day 30 (one month after vaccination)</time_frame>
        <population>All vaccinated participants with data available are included.</population>
        <group_list>
          <group group_id="O1">
            <title>V114-A</title>
            <description>Participants receive a single 0.5 mL intramuscular injection of V114 Formulation A on Day 1. Formulation A of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-A uses a unique excipient to improve stability of the vaccine against physical stress).</description>
          </group>
          <group group_id="O2">
            <title>V114-B</title>
            <description>Participants receive a single 0.5 mL intramuscular injection of V114 Formulation B on Day 1. Formulation B of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-B uses a unique excipient to improve stability of the vaccine against physical stress).</description>
          </group>
          <group group_id="O3">
            <title>Prevnar 13®</title>
            <description>Participants receive a single 0.5 mL intramuscular injection of Prevnar 13™ on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a ≥4-fold Rise From Baseline in Geometric Mean Concentrations (GMCs) of Serotype-specific Immunoglobulin G (IgG) Antibodies</title>
          <description>The percentage of participants with ≥4-fold rise from baseline in IgG GMCs of each common serotype (CS) and V114-specific serotype (VS) were compared in the V114 and Prevnar® 13 arms. Estimated GMT, GMT ratio, 95% CI, and p-values were obtained from a constrained longitudinal data analysis (cLDA) model.</description>
          <population>All vaccinated participants with data available are included.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
                <count group_id="O2" value="231"/>
                <count group_id="O3" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CS1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="215"/>
                    <count group_id="O3" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.2" lower_limit="72.14" upper_limit="83.55"/>
                    <measurement group_id="O2" value="69.8" lower_limit="63.15" upper_limit="75.83"/>
                    <measurement group_id="O3" value="65.4" lower_limit="58.63" upper_limit="71.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="215"/>
                    <count group_id="O3" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.3" lower_limit="51.45" upper_limit="64.98"/>
                    <measurement group_id="O2" value="46.5" lower_limit="39.70" upper_limit="53.42"/>
                    <measurement group_id="O3" value="31.3" lower_limit="25.16" upper_limit="37.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="215"/>
                    <count group_id="O3" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.8" lower_limit="65.25" upper_limit="77.66"/>
                    <measurement group_id="O2" value="63.7" lower_limit="56.91" upper_limit="70.15"/>
                    <measurement group_id="O3" value="62.1" lower_limit="55.29" upper_limit="68.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="215"/>
                    <count group_id="O3" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.3" lower_limit="45.43" upper_limit="59.13"/>
                    <measurement group_id="O2" value="47.0" lower_limit="40.16" upper_limit="53.88"/>
                    <measurement group_id="O3" value="48.1" lower_limit="41.27" upper_limit="55.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS6A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="215"/>
                    <count group_id="O3" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.6" lower_limit="67.20" upper_limit="79.36"/>
                    <measurement group_id="O2" value="77.2" lower_limit="71.01" upper_limit="82.64"/>
                    <measurement group_id="O3" value="77.1" lower_limit="70.88" upper_limit="82.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS6B</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="215"/>
                    <count group_id="O3" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.5" lower_limit="69.17" upper_limit="81.05"/>
                    <measurement group_id="O2" value="77.2" lower_limit="71.01" upper_limit="82.64"/>
                    <measurement group_id="O3" value="66.4" lower_limit="59.60" upper_limit="72.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS7F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="215"/>
                    <count group_id="O3" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.4" lower_limit="62.83" upper_limit="75.51"/>
                    <measurement group_id="O2" value="72.6" lower_limit="66.08" upper_limit="78.41"/>
                    <measurement group_id="O3" value="69.6" lower_limit="62.99" upper_limit="75.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS9V</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="215"/>
                    <count group_id="O3" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.1" lower_limit="64.77" upper_limit="77.23"/>
                    <measurement group_id="O2" value="71.6" lower_limit="65.10" upper_limit="77.55"/>
                    <measurement group_id="O3" value="65.0" lower_limit="58.15" upper_limit="71.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="215"/>
                    <count group_id="O3" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.9" lower_limit="50.98" upper_limit="64.54"/>
                    <measurement group_id="O2" value="48.8" lower_limit="41.98" upper_limit="55.73"/>
                    <measurement group_id="O3" value="49.1" lower_limit="42.19" upper_limit="55.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS18C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="215"/>
                    <count group_id="O3" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.8" lower_limit="65.25" upper_limit="77.66"/>
                    <measurement group_id="O2" value="77.7" lower_limit="71.51" upper_limit="83.06"/>
                    <measurement group_id="O3" value="70.6" lower_limit="63.96" upper_limit="76.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS19A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="215"/>
                    <count group_id="O3" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.3" lower_limit="58.52" upper_limit="71.61"/>
                    <measurement group_id="O2" value="67.9" lower_limit="61.22" upper_limit="74.09"/>
                    <measurement group_id="O3" value="64.5" lower_limit="57.67" upper_limit="70.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS19F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="215"/>
                    <count group_id="O3" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.7" lower_limit="52.85" upper_limit="66.32"/>
                    <measurement group_id="O2" value="71.6" lower_limit="65.10" upper_limit="77.55"/>
                    <measurement group_id="O3" value="62.6" lower_limit="55.76" upper_limit="69.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS22F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="215"/>
                    <count group_id="O3" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.3" lower_limit="64.77" upper_limit="77.23"/>
                    <measurement group_id="O2" value="71.2" lower_limit="64.61" upper_limit="77.12"/>
                    <measurement group_id="O3" value="1.9" lower_limit="0.51" upper_limit="4.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VS23F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="215"/>
                    <count group_id="O3" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2" lower_limit="65.74" upper_limit="78.08"/>
                    <measurement group_id="O2" value="77.2" lower_limit="71.01" upper_limit="82.64"/>
                    <measurement group_id="O3" value="71.5" lower_limit="64.94" upper_limit="77.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VS33F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="215"/>
                    <count group_id="O3" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.7" lower_limit="66.23" upper_limit="78.51"/>
                    <measurement group_id="O2" value="65.6" lower_limit="58.82" upper_limit="71.91"/>
                    <measurement group_id="O3" value="0.9" lower_limit="0.11" upper_limit="3.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 30 days after vaccination</time_frame>
      <desc>All participants who received study vaccination are included.</desc>
      <group_list>
        <group group_id="E1">
          <title>V114-A</title>
          <description>Participants receive a single 0.5 mL intramuscular injection of V114 Formulation A on Day 1. Formulation A of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-A uses a unique excipient to improve stability of the vaccine against physical stress).</description>
        </group>
        <group group_id="E2">
          <title>V114-B</title>
          <description>Participants receive a single 0.5 mL intramuscular injection of V114 Formulation B on Day 1. Formulation B of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-B uses a unique excipient to improve stability of the vaccine against physical stress).</description>
        </group>
        <group group_id="E3">
          <title>Prevnar 13®</title>
          <description>Participants receive a single 0.5 mL intramuscular injection of Prevnar 13™ on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="169" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="163" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="148" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="62" subjects_affected="56" subjects_at_risk="231"/>
                <counts group_id="E2" events="44" subjects_affected="41" subjects_at_risk="231"/>
                <counts group_id="E3" events="57" subjects_affected="51" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="231"/>
                <counts group_id="E2" events="30" subjects_affected="29" subjects_at_risk="231"/>
                <counts group_id="E3" events="24" subjects_affected="24" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="159" subjects_affected="145" subjects_at_risk="231"/>
                <counts group_id="E2" events="149" subjects_affected="140" subjects_at_risk="231"/>
                <counts group_id="E3" events="134" subjects_affected="124" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="231"/>
                <counts group_id="E2" events="38" subjects_affected="38" subjects_at_risk="231"/>
                <counts group_id="E3" events="29" subjects_affected="29" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="231"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="231"/>
                <counts group_id="E3" events="17" subjects_affected="14" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="53" subjects_affected="53" subjects_at_risk="231"/>
                <counts group_id="E2" events="45" subjects_affected="43" subjects_at_risk="231"/>
                <counts group_id="E3" events="35" subjects_affected="32" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="34" subjects_affected="28" subjects_at_risk="231"/>
                <counts group_id="E2" events="35" subjects_affected="29" subjects_at_risk="231"/>
                <counts group_id="E3" events="41" subjects_affected="38" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

